In 2024, Apeloa Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Apeloa Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 |
|---|---|
Total Scope 1 | 10,400a |
Total Scope 2 | |
Unspecified Calculation Method | 605,200a |
Total Scope 3 | N/A |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 6.3135a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Apeloa Pharmaceutical amounted to 615,600 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
In 2024, the total Scope 1 emissions of Apeloa Pharmaceutical were 10,400 metric tons of CO₂ equivalent (tCO₂e).a
In 2024, Apeloa Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 605,200 tCO₂e without specifying the calculation method.a
In 2024, Apeloa Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.a
In 2024, Apeloa Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 10,400 tCO₂e and total revenues of USD 1,647 millions. This translates into an emissions intensity of 6.31 tCO₂e per millions USD.a
In 2024, Apeloa Pharmaceutical reported a Scope 1 emissions intensity of 6.31 tCO₂e per millions USD. Compared to the peer group median of 25.37, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, Apeloa Pharmaceutical ranked 7 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Apeloa Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a